Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

• Main Authors: April W. Armstrong (Author), Tarannum Jaleel (Author), Joseph F. Merola (Author), Alice B. Gottlieb (Author), Saakshi Khattri (Author), Cameron C. Helt (Author), William N. Malatestinic (Author), Sarah E. Ross (Author), Marcus E. Ngantcha (Author), Kurt de Vlam (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239) and SPIRIT-P2 (NCT02349295) studies in patients wi...